Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXTENZA vs Topical Therapy for Allergic Conjunctivitis
NCT04708821Phase 4Completed
- Sponsor
- Clinical Research Center of Florida
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dexamethasone in allergic conjunctivitis (AC) (3 arms), sponsored by Clinical Research Center of Florida. Primary endpoint: Patient-reported treatment preference of self-administered topical therapy versus physician-administered therapy at 30 days. Started Apr 2021; status: completed.
02
Drugs
dexamethasone
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT04708821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708821.